Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > HLVX HilleVax > Company Executives
HLVX HilleVax
13.010
+1.160+9.79%
NamePositionSalaryService DateEducationAgeGenderUpdated
Dr. Robert M. Hershberg, M.D.,PhDChairman of the Board, President and Chief Executive Officer611.20K----58male04/29/2022
Mr. David A. SocksChief Financial Officer and Chief Business Officer528.36K----47male04/29/2022
Mr. Aditya Kohli, PhDChief Operating Officer and Director541.85K----34male04/29/2022
Dr. Astrid Borkowski, M.D.Chief Medical Officer------52female04/29/2022
Dr. Gary Dubin, M.D.Director------65male04/29/2022
Ms. Jeryl L. HillemanIndependent Director------64female04/29/2022
Mr. Patrick J. HeronIndependent Director------51male04/29/2022
Ms. Susan SilbermannIndependent Director------59female04/29/2022
Dr. Julie L. GerberdingIndependent Director------66female04/29/2022
Dr. Shelley Chu, PhDIndependent Director------52female04/29/2022
Dr. Jaime Sepulveda, D.Sc.Independent Director------68male04/29/2022
Company Overview More
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
CEO: Hershberg M.D., Ph.D., Robert M.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top